Fundraising Fox
/Companies
Sign in

Longboard Pharmaceuticals

San Diego, US · Founded 2020 · Delaware corporation · 19 employees on LinkedIn · 1 known investors

Find your way into Longboard Pharmaceuticals

Sign up to see every warm intro you have to Longboard Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Longboard Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule medicines targeting G protein-coupled receptors for neurological diseases, with an initial focus on rare conditions. Its lead candidate, bexicaserin (LP352), is an oral 5-HT2C receptor superagonist in development for seizures associated with developmental and epileptic encephalopathies; the company is now a subsidiary of Lundbeck.

BiotechHealthtech

Founders & leadership

KLKevin Lind
Kevin LindPresident & CEO
RKRandall Kaye
Randall KayeEVP & Chief Medical Officer
BRBrandi Roberts
Brandi RobertsChief Financial OfficerShe has held finance leadership roles at biotech firms spanning development through commercialization, with experience in IPOs, SEC compliance, M&A transactions, and clinical trials, including the $2.6 billion acquisition of Longboard by Lundbeck.
SSSteven Spector
Steven SpectorGeneral Counsel / Head of Business Development
COChad Orevillo
Chad OrevilloHead of Clinical OperationsChad Orevillo is Head of Clinical Operations at Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company developing small-molecule medicines targeting G protein-coupled receptors for neurological diseases.
LS
Laurie StelzerNamed on SEC filing
VAVincent Aurentz
Vincent AurentzMember of the Board Of Directors2020–2024Executive Officer at Hemoshear Therapeutics
CL
Chandra LeoNamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements

$56M disclosed across 1 of 2 rounds · 2020–2024

▶$56MraisedNov 2020 · 17 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Laurie StelzerDirector
  • Kevin R LindExecutive Officer, Director
  • Vincent AurentzDirector
  • Chandra LeoDirector
Offering amount
$56M
Amount sold
$56M
First sale
Oct 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

LeadIQLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.

Companies working in the same space as Longboard Pharmaceuticals.

Frequently asked questions

What does Longboard Pharmaceuticals do?
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule medicines targeting G protein-coupled receptors for neurological diseases, with an initial focus on rare conditions. Its lead candidate, bexicaserin (LP352), is an oral 5-HT2C receptor superagonist in development for seizures associated with developmental and epileptic encephalopathies; the company is now a subsidiary of Lundbeck.
Who are Longboard Pharmaceuticals's investors?
Longboard Pharmaceuticals's investors include Viking Global.
How much funding has Longboard Pharmaceuticals raised?
Longboard Pharmaceuticals has disclosed $56M raised across 1 of its 2 known rounds.
Where is Longboard Pharmaceuticals headquartered?
Longboard Pharmaceuticals is headquartered in San Diego, US.